Swedish medical equipment maker Elekta has entered a collaboration to use IBM Watson Health’s artificial intelligence (AI) based platform, Watson for Oncology, with its digital cancer care solutions.
Under the partnership, Elekta will sell Watson for Oncology as a clinical decision support feature within its care solutions such as the MOSAIQ Oncology Information System.
The Swedish firm is planning to offer both the platforms in the majority of the markets, including the US, Brazil, India, Australia, and select European and Asian countries.
Elekta CEO Richard Hausmann said: “Joining forces with IBM Watson Health positions Elekta as the first radiation therapy company to offer capabilities that combine conventional health information systems with AI and cognitive cloud computing.
“Our goal is to bring cutting-edge AI technology to the cancer care continuum, including treatment planning, enabling evidence-based treatment recommendations for every patient regardless of where they are treated.”
IBM developed Watson for Oncology in alliance with New York-based Memorial Sloan Kettering Cancer Center (MSK).
The platform provides patient information required by oncologists to deliver and rank treatment options, as well as link them to peer-reviewed studies curated by MSK.
It also contains vast volumes of medical literature aggregated from more than 300 medical journals, 200 textbooks, and approximately 15 million pages of text on various treatments.
IBM Watson Health oncology and life sciences vice-president Lisa Rometty said: “Oncologists around the world rely on MOSAIQ to support the treatment pathway, and we are eager to extend Watson for Oncology to more physicians and patients globally through Elekta’s sophisticated digital oncology solutions.”